CN1767078A - 制备镭-223的方法、生理学上可接受的制剂和试剂盒 - Google Patents
制备镭-223的方法、生理学上可接受的制剂和试剂盒 Download PDFInfo
- Publication number
- CN1767078A CN1767078A CNA2004100749238A CN200410074923A CN1767078A CN 1767078 A CN1767078 A CN 1767078A CN A2004100749238 A CNA2004100749238 A CN A2004100749238A CN 200410074923 A CN200410074923 A CN 200410074923A CN 1767078 A CN1767078 A CN 1767078A
- Authority
- CN
- China
- Prior art keywords
- acid
- radium
- preparation
- bone
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 229960005562 radium-223 Drugs 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 52
- 230000008569 process Effects 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims description 26
- 230000002285 radioactive effect Effects 0.000 claims description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 20
- -1 alkaline earth metal cation Chemical class 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 11
- 239000011707 mineral Substances 0.000 claims description 11
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 150000003009 phosphonic acids Chemical class 0.000 claims description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 9
- 239000000084 colloidal system Substances 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 8
- 150000001735 carboxylic acids Chemical class 0.000 claims description 7
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 6
- 229910017604 nitric acid Inorganic materials 0.000 claims description 6
- NDJKXXJCMXVBJW-UHFFFAOYSA-N heptadecane Chemical compound CCCCCCCCCCCCCCCCC NDJKXXJCMXVBJW-UHFFFAOYSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052768 actinide Inorganic materials 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000006386 neutralization reaction Methods 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- PSVQKOKKLWHNRP-UHFFFAOYSA-N 3-ethylheptane Chemical compound CCCCC(CC)CC PSVQKOKKLWHNRP-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- 150000001255 actinides Chemical class 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 239000012752 auxiliary agent Substances 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims description 3
- 229910052712 strontium Inorganic materials 0.000 claims description 3
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 abstract description 73
- 238000011282 treatment Methods 0.000 abstract description 23
- 210000004872 soft tissue Anatomy 0.000 abstract description 15
- 206010028980 Neoplasm Diseases 0.000 abstract description 11
- 208000018084 Bone neoplasm Diseases 0.000 abstract 1
- 230000005855 radiation Effects 0.000 description 27
- 239000000243 solution Substances 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 230000017105 transposition Effects 0.000 description 14
- 239000011347 resin Substances 0.000 description 13
- 229920005989 resin Polymers 0.000 description 13
- 239000000523 sample Substances 0.000 description 12
- 229910052705 radium Inorganic materials 0.000 description 10
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 10
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 229910052704 radon Inorganic materials 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000012217 radiopharmaceutical Substances 0.000 description 7
- 229940121896 radiopharmaceutical Drugs 0.000 description 7
- 230000002799 radiopharmaceutical effect Effects 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- HCWPIIXVSYCSAN-YPZZEJLDSA-N radium-224 Chemical compound [224Ra] HCWPIIXVSYCSAN-YPZZEJLDSA-N 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- HCWPIIXVSYCSAN-IGMARMGPSA-N Radium-226 Chemical compound [226Ra] HCWPIIXVSYCSAN-IGMARMGPSA-N 0.000 description 5
- 230000005250 beta ray Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- SYUHGPGVQRZVTB-OIOBTWANSA-N radon-219 atom Chemical compound [219Rn] SYUHGPGVQRZVTB-OIOBTWANSA-N 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 230000002308 calcification Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000000505 pernicious effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 229940122361 Bisphosphonate Drugs 0.000 description 3
- JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 3
- 150000004663 bisphosphonates Chemical class 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000002805 bone matrix Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- NFDRPXJGHKJRLJ-UHFFFAOYSA-N edtmp Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CCN(CP(O)(O)=O)CP(O)(O)=O NFDRPXJGHKJRLJ-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- WABPQHHGFIMREM-RNFDNDRNSA-N lead-211 Chemical compound [211Pb] WABPQHHGFIMREM-RNFDNDRNSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 229940120146 EDTMP Drugs 0.000 description 2
- WVYCUPGXDCILQL-UHFFFAOYSA-N P(O)(O)=O.P(O)(O)=O.C Chemical class P(O)(O)=O.P(O)(O)=O.C WVYCUPGXDCILQL-UHFFFAOYSA-N 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- RYXHOMYVWAEKHL-OUBTZVSYSA-N astatine-211 Chemical compound [211At] RYXHOMYVWAEKHL-OUBTZVSYSA-N 0.000 description 2
- JCXGWMGPZLAOME-NJFSPNSNSA-N bismuth-211 Chemical compound [211Bi] JCXGWMGPZLAOME-NJFSPNSNSA-N 0.000 description 2
- 201000001531 bladder carcinoma Diseases 0.000 description 2
- 150000001669 calcium Chemical class 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000012539 chromatography resin Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003608 radiolysis reaction Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- SYUHGPGVQRZVTB-YPZZEJLDSA-N radon-220 atom Chemical compound [220Rn] SYUHGPGVQRZVTB-YPZZEJLDSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 229940006509 strontium-89 Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 229940127048 Metastron Drugs 0.000 description 1
- 206010027926 Monoplegia Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000005262 alpha decay Effects 0.000 description 1
- BSJGASKRWFKGMV-UHFFFAOYSA-L ammonia dichloroplatinum(2+) Chemical compound N.N.Cl[Pt+2]Cl BSJGASKRWFKGMV-UHFFFAOYSA-L 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- WABPQHHGFIMREM-BKFZFHPZSA-N lead-212 Chemical compound [212Pb] WABPQHHGFIMREM-BKFZFHPZSA-N 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 238000011362 radionuclide therapy Methods 0.000 description 1
- 150000003255 radium Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 1
- AHBGXTDRMVNFER-FCHARDOESA-L strontium-89(2+);dichloride Chemical compound [Cl-].[Cl-].[89Sr+2] AHBGXTDRMVNFER-FCHARDOESA-L 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Compounds Of Unknown Constitution (AREA)
- Biological Depolymerization Polymers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Materials For Medical Uses (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Description
核素 | 223Ra | 219Rn | 215Po | 211Pb | 211Bi | 207Tl |
α-能量 | 5.64MeV | 6.75MeV | 7.39MeV | 6.55MeV | ||
β-能量(最大) | 0.47MeV | 0.47MeV | ||||
能量分数 | 0.207 | 0.248 | 0.271 | ≤0.017 | 0.24 | ≤0.017 |
组织 | 6小时 | 3天 |
股骨 | 25.86±1.99 | 34.55±7.87 |
血 | 0.20±0.23 | 0.05±0.10 |
肾 | 4.04±0.33 | 0.38±0.08 |
肝 | 0.89±0.18 | 0.22±0.32 |
肺 | 0.59±0.56 | 0.06±0.07 |
肌肉 | 0.72±0.39 | 0.30±0.16 |
心脏 | 0.10±0.10 | 0.06±0.07 |
脑 | 0.04±0.01 | 0.12±0.12 |
脾 | 4.06±1.4 | 1.46±0.54 |
小肠 | 0.79±0.26 | 0.04±0.03 |
大肠 | 2.30±0.60 | 0.13±0.02 |
Claims (25)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO19990001 | 1999-01-04 | ||
NO990001A NO310544B1 (no) | 1999-01-04 | 1999-01-04 | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998161020A Division CN1194764C (zh) | 1999-01-04 | 1999-12-17 | 镭-223在制备用于治疗影响骨的疾病的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1767078A true CN1767078A (zh) | 2006-05-03 |
CN1767078B CN1767078B (zh) | 2012-01-11 |
Family
ID=19902803
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004100749238A Expired - Lifetime CN1767078B (zh) | 1999-01-04 | 1999-12-17 | 制备镭-223的方法、生理学上可接受的制剂和试剂盒 |
CNB998161020A Expired - Lifetime CN1194764C (zh) | 1999-01-04 | 1999-12-17 | 镭-223在制备用于治疗影响骨的疾病的药物中的用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998161020A Expired - Lifetime CN1194764C (zh) | 1999-01-04 | 1999-12-17 | 镭-223在制备用于治疗影响骨的疾病的药物中的用途 |
Country Status (25)
Country | Link |
---|---|
US (2) | US6635234B1 (zh) |
EP (1) | EP1140212B1 (zh) |
JP (2) | JP4649044B2 (zh) |
KR (1) | KR100671387B1 (zh) |
CN (2) | CN1767078B (zh) |
AT (1) | ATE331534T1 (zh) |
AU (1) | AU774991B2 (zh) |
BE (1) | BE2014C028I2 (zh) |
BR (1) | BR9916768A (zh) |
CA (1) | CA2358498C (zh) |
CY (2) | CY1105634T1 (zh) |
DE (1) | DE69932183T2 (zh) |
DK (1) | DK1140212T3 (zh) |
EA (1) | EA003496B1 (zh) |
ES (1) | ES2268888T3 (zh) |
HK (1) | HK1090750A1 (zh) |
IL (1) | IL144135A0 (zh) |
LU (1) | LU92425I2 (zh) |
MX (1) | MXPA01006823A (zh) |
NO (2) | NO310544B1 (zh) |
NZ (3) | NZ545023A (zh) |
PT (1) | PT1140212E (zh) |
TR (3) | TR200201442T2 (zh) |
WO (1) | WO2000040275A2 (zh) |
ZA (1) | ZA200105431B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102985980A (zh) * | 2010-04-30 | 2013-03-20 | 艾尔格塔公司 | 同位素制备方法 |
CN103003889A (zh) * | 2010-04-30 | 2013-03-27 | 艾尔格塔公司 | 同位素制备方法 |
CN108472555A (zh) * | 2016-01-05 | 2018-08-31 | 拜耳公司 | 同位素制备方法 |
CN112789691A (zh) * | 2018-09-26 | 2021-05-11 | 奥兰诺医药公司 | 由含钍-228及其子体的水溶液生产铅-212的方法 |
CN113056290A (zh) * | 2018-11-15 | 2021-06-29 | 奥兰诺医药公司 | 制备具有高镭-228含量的至少一个发生器的方法 |
CN115869658A (zh) * | 2022-12-29 | 2023-03-31 | 中国核动力研究设计院 | 用于制备Ra-223的分离系统及其分离方法、应用和制备方法 |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO310544B1 (no) * | 1999-01-04 | 2001-07-23 | Algeta As | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
NO314537B1 (no) * | 1999-12-06 | 2003-04-07 | Anticancer Therapeutic Inv Sa | Reseptorbindende konjugater |
NO313180B1 (no) * | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
AUPQ923100A0 (en) * | 2000-08-07 | 2000-08-31 | Peplin Research Pty Ltd | Treatment of prostate cancer |
AU2002364051A1 (en) * | 2002-01-24 | 2003-09-02 | Children's Medical Center Corporation | Anti-cancer combination and use thereof |
GB0213261D0 (en) * | 2002-06-10 | 2002-07-17 | Anticancer Therapeutic Inv Sa | Method |
GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
WO2004096293A2 (en) * | 2003-04-30 | 2004-11-11 | Ramot At Tel Aviv University Ltd. | Method and device for radiotherapy |
CA2555435C (en) * | 2004-02-20 | 2011-07-12 | Algeta As | Alpha-emitting hydroxyapatite particles |
DE102004022200B4 (de) * | 2004-05-05 | 2006-07-20 | Actinium Pharmaceuticals, Inc. | Radium-Target sowie Verfahren zu seiner Herstellung |
US7914766B1 (en) * | 2004-06-03 | 2011-03-29 | Ut-Battelle Llc | Inorganic resins for clinical use of 213Bi generators |
GB0423565D0 (en) * | 2004-10-22 | 2004-11-24 | Algeta As | Formulation |
SI2510952T1 (sl) * | 2005-07-26 | 2019-01-31 | Aplha Tau Medical Ltd. | Radioaktivni površinski vir in postopek za izdelavo le-tega |
US8709380B1 (en) * | 2006-02-07 | 2014-04-29 | Sirius Medicine, Llc | Targeting agents for enhancing radiation therapy |
DE102006008023B4 (de) * | 2006-02-21 | 2008-05-29 | Actinium Pharmaceuticals, Inc. | Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets |
WO2008028664A1 (en) | 2006-09-08 | 2008-03-13 | Actinium Pharmaceuticals, Inc. | Method for the purification of radium from different sources |
EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
CA2895356A1 (en) | 2012-12-19 | 2014-06-26 | Bayer Pharma Aktiengesellschaft | Combination comprising radium-223 for the treatment of cancer |
GB201314718D0 (en) * | 2013-08-16 | 2013-10-02 | Algeta As | Quantification method |
CN105934256B (zh) | 2013-12-03 | 2019-12-27 | 拜耳制药股份公司 | Pi3k-抑制剂的组合产品 |
EP3077003A1 (en) | 2013-12-03 | 2016-10-12 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
MA39147B1 (fr) | 2013-12-17 | 2019-12-31 | Esteve Labor Dr | Combinaisons d'inhibiteurs de la recapture de sérotonine-norépinéphrine (snri) et de ligands des récepteurs sigma |
WO2016083739A1 (fr) | 2014-11-26 | 2016-06-02 | Rhodia Operations | Composition de lanthane et d'actinium-227 |
GB201600153D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
CZ2016821A3 (cs) * | 2016-12-22 | 2018-07-04 | České vysoké učení technické v Praze | Kombinace pro radionuklidovou terapii pro použití jako léčivo |
TW201840319A (zh) | 2017-02-24 | 2018-11-16 | 德商拜耳廠股份有限公司 | Atr激酶抑制劑與鐳-223鹽之組合 |
CA3059534A1 (en) | 2017-05-11 | 2018-11-15 | Alpha Tau Medical Ltd. | Polymer coatings for brachytherapy devices |
CA3094785A1 (en) | 2018-04-02 | 2019-10-10 | Alpha Tau Medical Ltd. | Controlled release of radionuclides |
EP3563875A1 (en) * | 2018-05-04 | 2019-11-06 | Ceské vysoké ucení technické v Praze | Radium for radionuclide therapy, in combination with calcium metabolism affecting treatment |
LU100900B1 (de) * | 2018-08-10 | 2020-02-17 | Thomas Melchior Homann | Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen |
US20220152228A1 (en) * | 2019-03-01 | 2022-05-19 | Washington University | Compositions and methods for radiotherapy using chelated radiotherapeutic agents and non-target tissue blockade |
RU2752845C1 (ru) * | 2020-05-13 | 2021-08-11 | Акционерное Общество "Наука И Инновации" | Способ получения высокочистого радия-223 |
WO2022130195A1 (en) * | 2020-12-16 | 2022-06-23 | Alpha Tau Medical Ltd. | Diffusing alpha-emitters radiation therapy with enhanced beta treatment |
CN113066598B (zh) * | 2021-03-25 | 2023-08-08 | 中国科学院近代物理研究所 | 一种从高能质子束辐照232Th靶引起的散裂反应中分离纯化223Ra的方法 |
US11964168B2 (en) | 2021-06-10 | 2024-04-23 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for prostate cancer |
US12042668B2 (en) | 2021-06-10 | 2024-07-23 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for squamous cell carcinoma |
WO2023159230A1 (en) | 2022-02-21 | 2023-08-24 | Bayer Healthcare Llc | System, method and device for delivery of a therapeutic or diagnostic agent |
WO2023159229A1 (en) | 2022-02-21 | 2023-08-24 | Bayer Healthcare Llc | System, method and device for delivery of a therapeutic or diagnostic agent |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH668489A5 (de) * | 1982-01-22 | 1988-12-30 | Vnii Mineralnogo Syrya | Radiometrisches verfahren zur bestimmung der konzentration natuerlicher radiumisotope und einrichtung zur durchfuehrung des verfahrens. |
JPH04501265A (ja) * | 1988-10-14 | 1992-03-05 | マリンクロッド・インコーポレイテッド | ラジオ標識粒状組成物 |
US4970062A (en) * | 1989-05-30 | 1990-11-13 | The United States Of America As Represented By The United States Department Of Energy | Colloid labelled with radionuclide and method |
AU3177893A (en) * | 1991-11-14 | 1993-06-15 | Battelle Memorial Institute | Method for diagnosing and treating cancer |
AU683893B2 (en) * | 1993-05-17 | 1997-11-27 | Immunomedics Inc. | Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates |
US5809394A (en) * | 1996-12-13 | 1998-09-15 | Battelle Memorial Institute | Methods of separating short half-life radionuclides from a mixture of radionuclides |
US6117413A (en) * | 1997-11-12 | 2000-09-12 | Battelle Memorial Institute | Radionuclide-binding compound, a radionuclide delivery system, a method of making a radium complexing compound, a method of extracting a radionuclide, and a method of delivering a radionuclide |
NO310544B1 (no) * | 1999-01-04 | 2001-07-23 | Algeta As | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
NO314537B1 (no) * | 1999-12-06 | 2003-04-07 | Anticancer Therapeutic Inv Sa | Reseptorbindende konjugater |
NO312708B1 (no) * | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
NO313180B1 (no) * | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
GB0213261D0 (en) * | 2002-06-10 | 2002-07-17 | Anticancer Therapeutic Inv Sa | Method |
US20060228297A1 (en) * | 2003-04-15 | 2006-10-12 | Roy Larsen | Thorium-227 for use in radiotherapy of soft tissue disease |
GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
-
1999
- 1999-01-04 NO NO990001A patent/NO310544B1/no not_active IP Right Cessation
- 1999-12-17 BR BR9916768-9A patent/BR9916768A/pt not_active Application Discontinuation
- 1999-12-17 PT PT99960058T patent/PT1140212E/pt unknown
- 1999-12-17 WO PCT/NO1999/000392 patent/WO2000040275A2/en active Search and Examination
- 1999-12-17 TR TR2002/01442T patent/TR200201442T2/xx unknown
- 1999-12-17 CN CN2004100749238A patent/CN1767078B/zh not_active Expired - Lifetime
- 1999-12-17 DK DK99960058T patent/DK1140212T3/da active
- 1999-12-17 KR KR1020017008497A patent/KR100671387B1/ko active Protection Beyond IP Right Term
- 1999-12-17 TR TR2001/02707T patent/TR200102707T2/xx unknown
- 1999-12-17 AU AU17004/00A patent/AU774991B2/en active Active
- 1999-12-17 JP JP2000592029A patent/JP4649044B2/ja not_active Expired - Lifetime
- 1999-12-17 NZ NZ545023A patent/NZ545023A/en not_active IP Right Cessation
- 1999-12-17 NZ NZ534618A patent/NZ534618A/xx not_active IP Right Cessation
- 1999-12-17 MX MXPA01006823A patent/MXPA01006823A/es active IP Right Grant
- 1999-12-17 EA EA200100642A patent/EA003496B1/ru not_active IP Right Cessation
- 1999-12-17 CA CA002358498A patent/CA2358498C/en not_active Expired - Lifetime
- 1999-12-17 IL IL14413599A patent/IL144135A0/xx not_active IP Right Cessation
- 1999-12-17 ES ES99960058T patent/ES2268888T3/es not_active Expired - Lifetime
- 1999-12-17 NZ NZ513135A patent/NZ513135A/en not_active IP Right Cessation
- 1999-12-17 DE DE69932183T patent/DE69932183T2/de not_active Expired - Lifetime
- 1999-12-17 AT AT99960058T patent/ATE331534T1/de active
- 1999-12-17 EP EP99960058A patent/EP1140212B1/en not_active Expired - Lifetime
- 1999-12-17 CN CNB998161020A patent/CN1194764C/zh not_active Expired - Lifetime
- 1999-12-17 TR TR2002/01440T patent/TR200201440T2/xx unknown
-
2000
- 2000-01-03 US US09/476,569 patent/US6635234B1/en not_active Expired - Lifetime
-
2001
- 2001-07-02 ZA ZA200105431A patent/ZA200105431B/en unknown
-
2003
- 2003-06-12 US US10/459,941 patent/US20030206857A1/en not_active Abandoned
-
2006
- 2006-09-28 CY CY20061101404T patent/CY1105634T1/el unknown
- 2006-11-02 HK HK06112108.8A patent/HK1090750A1/xx not_active IP Right Cessation
-
2010
- 2010-04-20 JP JP2010096736A patent/JP5433490B2/ja not_active Expired - Lifetime
-
2014
- 2014-04-09 LU LU92425C patent/LU92425I2/fr unknown
- 2014-05-07 BE BE2014C028C patent/BE2014C028I2/fr unknown
- 2014-05-09 NO NO2014010C patent/NO2014010I1/no not_active IP Right Cessation
- 2014-05-13 CY CY2014020C patent/CY2014020I1/el unknown
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102985980A (zh) * | 2010-04-30 | 2013-03-20 | 艾尔格塔公司 | 同位素制备方法 |
CN103003889A (zh) * | 2010-04-30 | 2013-03-27 | 艾尔格塔公司 | 同位素制备方法 |
CN102985980B (zh) * | 2010-04-30 | 2015-08-12 | 艾尔格塔公司 | 同位素制备方法 |
CN103003889B (zh) * | 2010-04-30 | 2016-01-20 | 艾尔格塔公司 | 同位素制备方法 |
CN105654999A (zh) * | 2010-04-30 | 2016-06-08 | 拜耳股份公司 | 同位素制备方法 |
CN108472555A (zh) * | 2016-01-05 | 2018-08-31 | 拜耳公司 | 同位素制备方法 |
CN112789691A (zh) * | 2018-09-26 | 2021-05-11 | 奥兰诺医药公司 | 由含钍-228及其子体的水溶液生产铅-212的方法 |
CN112789691B (zh) * | 2018-09-26 | 2024-02-20 | 奥兰诺医药公司 | 由含钍-228及其子体的水溶液生产铅-212的方法 |
CN113056290A (zh) * | 2018-11-15 | 2021-06-29 | 奥兰诺医药公司 | 制备具有高镭-228含量的至少一个发生器的方法 |
CN115869658A (zh) * | 2022-12-29 | 2023-03-31 | 中国核动力研究设计院 | 用于制备Ra-223的分离系统及其分离方法、应用和制备方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1194764C (zh) | 镭-223在制备用于治疗影响骨的疾病的药物中的用途 | |
Breeman et al. | Radiolabelling DOTA-peptides with 68 Ga | |
NO313180B1 (no) | Bensökende alfapartikkel emitterende radiofarmasöytika | |
CN111920968B (zh) | 一种可视化放射性炭微球及其制备方法和用途 | |
CN106415734B (zh) | 生产43Sc放射性核素及其放射性药物用于正电子发射断层显像 | |
Lathrop et al. | Rapid incorporation of short-lived cyclotron-produced radionuclides into radiopharmaceuticals | |
Khalid et al. | Evaluation of carrier added and no carrier added 90 Y-EDTMP as bone seeking therapeutic radiopharmaceutical. | |
Shirvani-Arani et al. | Production, quality control and biodistribution studies of thulium-170-labeled ethylenediamine (tetramethylene phosphonic acid) | |
Qiu et al. | Feasible Strategy for Large-Scale Production of 224Ra as a Promising α-Emitting Therapy Radionuclide | |
CN105744960A (zh) | 包括铜放射性同位素的抗癌药物 | |
Ferro-Flores et al. | [166Dy] Dy/166Ho hydroxide macroaggregates: an in vivo generator system for radiation synovectomy | |
Zakaly et al. | Biokinetic model development of177Lu-labeled methylene diphosphonate as a radiopharmaceutical treatment | |
Doroudi et al. | The stability of 99mTc-MIBI (Sestamibi) complex samples which prepared under ultrasound irradiation technique versus boiling water bath method | |
CN1268629C (zh) | 放射性锝-99m标记的异腈类配合物及其制备方法和应用 | |
Zakaly et al. | Labeling of ethylenediamine tetramethylene phosphonate with 153Sm and 177Lu, comparison study | |
Rabiei et al. | Pharmacokinetic studies and human absorbed dose estimation of 68 Ga-(4 {[(bis (phosphonomethyl)) carbamoyl] methyl}-7, 10-bis (carboxymethy l)-1, 4, 7, 10-tetraazacyclododec-1-yl) acetic acid | |
CN1075389C (zh) | 铼核素标记碘化油溶胶制剂、制备方法及其应用 | |
CN104971368A (zh) | 内嵌放射性金属富勒烯衍生物及其制备方法与在肿瘤诊疗中的应用 | |
Fakhari et al. | Production, quality control, biodistribution assessment and preliminary dose evaluation of 166Ho-alendronate as a bone marrow ablative agent | |
Wendt III et al. | Dosimetric implications of the potential radionuclidic impurities in 153Sm-DOTMP | |
Dormehl | Novel phosphonate containing ligands for optimised targeted radiotherapy of neoplastic bone disease: using animal models and scintigraphy | |
Kerdjoudj | Scandium complexes: physico-chemical study and evaluation of stability in vitro and in vivo for nuclear medicine application | |
Kairemo | PBPK modeling for dosimetry of non-clinical and pediatric radioimmunotherapy | |
Kabalka | Molecular Medicine: Synthesis and In Vivo Detection of Agents for use in Boron Neutron Capture Therapy. Final Report | |
Saichi et al. | {sup 153}-EDTMP for palliation of pain from osseous metastases: Preparation and biodistribution studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1090750 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1090750 Country of ref document: HK |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151130 Address after: Oslo Patentee after: BAYER AG Address before: Oslo Patentee before: Anticancer Therapeutic Inventions AS |
|
CX01 | Expiry of patent term |
Granted publication date: 20120111 |
|
CX01 | Expiry of patent term |